Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACAT1 | P24752 | 1/20 | 1.00 |
| ▸ | PLK1 | P53350 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9365137 | 1.00 | ACAT1 (1.00) | ACAT1PLK1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL9361027 | 1.00 | ACAT1 (1.00) | ACAT1PLK1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL9361036 | 1.00 | ACAT1 (1.00) | ACAT1PLK1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL9365235 | 1.00 | ACAT1 (1.00) | ACAT1PLK1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL9361187 | 1.00 | ACAT1 (1.00) | ACAT1PLK1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL9361218 | 0.94 | ACAT1 (0.89) | ACAT1PLK1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL9365882 | 0.94 | ACAT1 (0.89) | ACAT1PLK1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL9365182 | 0.94 | ACAT1 (0.89) | ACAT1PLK1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL9365133 | 0.93 | ACAT1 (0.87) | ACAT1PLK1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL9362328 | 0.93 | ACAT1 (0.87) | ACAT1PLK1MAPK1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003513909-A | — | — | 2003-04-15 | — | — | JP | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0424194-B1 | Benzanilide derivatives and their use as anti-atherosclerotic agents | RHONE POULENC SANTE (FR) | 1994-08-31 | — | — | EP | claimed |
| US-5159114-A | Anticholesterol agents | RHONE-POULENC SANTE (FR) | 1992-10-27 | — | — | US | claimed |
| EP-0424194-A2 | Benzanilide derivatives and their use as anti-atherosclerotic agents | RHONE-POULENC SANTE (FR) | 1991-04-24 | — | — | EP | claimed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023220930-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS CROSS-REFERENCES TO RELATED APPLICATIONS | INCREVET, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225492-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | INCREVET, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230372374-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS | INCREVET, INC. | 2023-11-23 | — | — | US | disclosed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| EP-0424194-B1 | Benzanilide derivatives and their use as anti-atherosclerotic agents | RHONE POULENC SANTE (FR) | 1994-08-31 | — | — | EP | disclosed |
| US-5159114-A | Anticholesterol agents | RHONE-POULENC SANTE (FR) | 1992-10-27 | — | — | US | disclosed |
| EP-0424194-A2 | Benzanilide derivatives and their use as anti-atherosclerotic agents | RHONE-POULENC SANTE (FR) | 1991-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372374-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS | SLC5A2, SLC5A1, SLC2A8 | ACAT1 3476/4885PLK1 4303/4885MAPK1 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.